Emicerfont in Irritable Bowel Syndrome

Phase 2, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Emicerfont with Placebo (2 arms). Primary endpoints: Percent change from Baseline in Laser Doppler regional Rectal Mucosal Blood Flow (RMBF) in response to physiological stress (cold water pressor test) at Day 3 and Percent Change from Baseline in Laser Doppler regional RMBF in response to psychological stress (dichotomous listening test) at Day 3. Started Dec 2006; status: completed.